Risk of requiring allogeneic blood transfusion (30 days post‐surgery) · people aged 18 and over undergoing vascular surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk of reoperation or repeat procedure for bleeding within 7 days · people aged 18 and over undergoing vascular surgery
It is very uncertain whether summary of findings: Fibrin sealant changes risk of reoperation or repeat procedure for bleeding within 7 days compared with usual care (very low certainty).
1 finding from 1 review
Intervention not reported
mg/day LDL cholesterol · participants with normal or abnormal lipid profiles
The intervention showed no clear difference in mg/day LDL cholesterol (high certainty).
1 finding from 1 review
Intervention not reported
mg/day LDL cholesterol · participants with normal or abnormal lipid profiles
The intervention showed no clear difference in mg/day LDL cholesterol (moderate certainty).
1 finding from 1 review
Intervention not reported
mg/day LDL cholesterol · participants with normal or abnormal lipid profiles
The intervention showed no clear difference in mg/day LDL cholesterol (moderate certainty).
1 finding from 1 review
Intervention not reported
mg/day LDL cholesterol · participants with normal or abnormal lipid profiles
The intervention showed no clear difference in mg/day LDL cholesterol (high certainty).
1 finding from 1 review
Intervention not reported
Pravastatin 10 to 80 mg/day (6 to 156 weeks) · participants with normal or abnormal lipid profiles
The review found no eligible studies for this question.
1 finding from 1 review
Number of bleeding days in first month · women seeking emergency contraception
1 finding from 1 review
Transfusion‐free interval (days) · people with non‐transfusion‐dependent β‐thalassaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Transfusion‐free interval (days) · people with non‐transfusion‐dependent β‐thalassaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Transfusion‐free interval (days) · people with non‐transfusion‐dependent β‐thalassaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Transfusion‐free interval (days) · people with non‐transfusion‐dependent β‐thalassaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total oocytes ‐ Normoresponders ‐ Donor oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists) · assisted reproduction technology cycles
1 finding from 1 review
Total oocytes ‐ PCOS (high‐responders) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) · assisted reproduction technology cycles
1 finding from 1 review
MII oocytes ‐ PCOS (high‐responders) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) · assisted reproduction technology cycles
1 finding from 1 review
Duration of stimulation (days) ‐ PCOS (high‐responders) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) · assisted reproduction technology cycles
1 finding from 1 review
Total dose of gonadotropins (IU) ‐ Normoresponders ‐ Donor oocytes ‐ Early ophase stimulation protocol ‐ Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists · assisted reproduction technology cycles
1 finding from 1 review
Total dose of gonadotropins (IU) ‐ PCOS (high‐responders) ‐ Own oocytes ‐ Early phase stumulation protocol ‐ Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) · assisted reproduction technology cycles
1 finding from 1 review
Moderate or severe OHSS ‐ Normoresponders ‐ Donor oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists) · assisted reproduction technology cycles
1 finding from 1 review
Live birth or ongoing pregnancy sensitivity analysis ‐ PCOS (high‐responders) ‐ own oocytes ‐ early phase stimulation protocol ‐ frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) · assisted reproduction technology cycles
Summary of findings table ‐ Progestogens showed no clear difference in live birth or ongoing pregnancy sensitivity analysis ‐ PCOS… compared with gnRH antagonists; GRADE not reported.
1 finding from 1 review